1. Home
  2. AKTX vs PMN Comparison

AKTX vs PMN Comparison

Compare AKTX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • PMN
  • Stock Information
  • Founded
  • AKTX N/A
  • PMN 2004
  • Country
  • AKTX United States
  • PMN Canada
  • Employees
  • AKTX N/A
  • PMN N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • AKTX Health Care
  • PMN Health Care
  • Exchange
  • AKTX Nasdaq
  • PMN Nasdaq
  • Market Cap
  • AKTX 32.8M
  • PMN 29.8M
  • IPO Year
  • AKTX N/A
  • PMN N/A
  • Fundamental
  • Price
  • AKTX $1.08
  • PMN $0.95
  • Analyst Decision
  • AKTX
  • PMN
  • Analyst Count
  • AKTX 0
  • PMN 0
  • Target Price
  • AKTX N/A
  • PMN N/A
  • AVG Volume (30 Days)
  • AKTX 27.7K
  • PMN 43.9K
  • Earning Date
  • AKTX 02-24-2025
  • PMN 03-31-2025
  • Dividend Yield
  • AKTX N/A
  • PMN N/A
  • EPS Growth
  • AKTX N/A
  • PMN N/A
  • EPS
  • AKTX N/A
  • PMN N/A
  • Revenue
  • AKTX N/A
  • PMN N/A
  • Revenue This Year
  • AKTX N/A
  • PMN N/A
  • Revenue Next Year
  • AKTX N/A
  • PMN N/A
  • P/E Ratio
  • AKTX N/A
  • PMN N/A
  • Revenue Growth
  • AKTX N/A
  • PMN N/A
  • 52 Week Low
  • AKTX $0.90
  • PMN $0.87
  • 52 Week High
  • AKTX $4.40
  • PMN $2.61
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 43.34
  • PMN 52.16
  • Support Level
  • AKTX $1.10
  • PMN $0.88
  • Resistance Level
  • AKTX $1.33
  • PMN $1.03
  • Average True Range (ATR)
  • AKTX 0.15
  • PMN 0.06
  • MACD
  • AKTX -0.01
  • PMN 0.00
  • Stochastic Oscillator
  • AKTX 5.97
  • PMN 46.67

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: